```html

Janus Kinase (JAK) Inhibitor–Related Infections

Overview

Janus kinase (JAK) inhibitors are a class of oral or injectable medications that block the activity of one or more of the JAK enzymes (JAK1, JAK2, JAK3, and TYK2). By interfering with the JAK‑STAT signaling pathway, they reduce inflammation and modify immune responses, making them valuable for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, atopic dermatitis, and some hematologic malignancies.

Because JAK inhibitors dampen immune surveillance, patients on these drugs are at increased risk for bacterial, viral, fungal, and opportunistic infections. The phenomenon is usually described as “JAK inhibitor–related infection.” It does not represent a single disease entity but a spectrum of infections that share a common precipitant—the medication.

Who is affected? Anyone prescribed a JAK inhibitor can develop an infection, but the risk is higher in:

• Adults ≥ 65 years old
• Individuals with pre‑existing lung disease, diabetes, chronic kidney disease, or a history of recurrent infections
• Patients receiving high‑dose or multiple immunosuppressants (e.g., corticosteroids, biologics)
• Those with latent infections such as tuberculosis (TB) or hepatitis B/C that reactivate under immunosuppression

Prevalence – Large pharmacovigilance databases estimate that infections occur in 15‑30 % of patients on JAK inhibitors, with serious infections (requiring hospitalization) in 2‑5 % over a 12‑month period.<sup>1,2</sup> The risk varies by drug (e.g., tofacitinib, baricitinib, upadacitinib, filgotinib) and underlying disease.

Symptoms

Because the infections can involve any organ system, the symptom profile is broad. Below is a comprehensive list grouped by the most commonly affected systems.

General / Constitutional

• Fever or chills – often the first clue.
• Fatigue, malaise – may be mistaken for underlying disease activity.
• Unexplained weight loss – especially in chronic infections such as TB.

Respiratory

• Cough (productive or dry)
• Shortness of breath or wheezing
• Pleuritic chest pain
• Upper‑respiratory symptoms (sore throat, sinus congestion) – could herald viral or bacterial sinusitis.

Gastrointestinal

• Abdominal pain or cramping
• Nausea, vomiting, or diarrhea (may be watery, bloody, or contain mucus)
• Hepatomegaly or right‑upper‑quadrant pain – may indicate opportunistic hepatitis.

Dermatologic

• New or worsening skin lesions: papules, pustules, vesicles, or ulcerated nodules.
• Herpes zoster (shingles) – the most common viral infection reported with JAK inhibitors.
• Fungal infections of the nail or intertriginous areas.

Genitourinary

• Dysuria, frequency, or urgency
• Flank pain or hematuria – could represent pyelonephritis.

Neurologic / Central Nervous System

• Headache, meningismus, or altered mental status – concerning for meningitis or encephalitis.
• Focal neurological deficits if a brain abscess or opportunistic infection is present.

Other Specific Infections

• Herpes simplex virus (HSV) – oral or genital lesions.
• Human papillomavirus (HPV) warts – may become extensive.
• Mycobacterial infections – pulmonary or disseminated TB, atypical mycobacteria.
• Fungal infections – candidiasis, pneumocystis jirovecii pneumonia (PCP), histoplasmosis, cryptococcosis.

Causes and Risk Factors

Mechanistic Cause

JAK inhibitors block cytokine signaling pathways that are crucial for immune cell activation, proliferation, and antimicrobial defense. Key cytokines affected include interleukins (IL‑2, IL‑6, IL‑12, IL‑23), interferons, and granulocyte‑macrophage colony‑stimulating factor (GM‑CSF). Inhibition reduces the ability of T‑cells, NK cells, neutrophils, and macrophages to recognize and eliminate pathogens.

Drug‑Specific Factors

• Tofacitinib – non‑selective (JAK1/3) and associated with higher herpes zoster rates.
• Baricitinib – JAK1/2 inhibition; linked to increased rates of serious bacterial infections and opportunistic fungal infections.
• Upadacitinib & Filgotinib – more JAK1 selective; still carry a measurable infection risk.

Patient‑Related Risk Factors

• Age > 65 years
• Concurrent high‑dose glucocorticoids (> 10 mg prednisone equivalent daily)
• History of chronic lung disease (COPD, interstitial lung disease)
• Diabetes mellitus or poor glycemic control
• Renal insufficiency (eGFR < 30 mL/min/1.73 m²)
• Positive screening for latent TB, hepatitis B/C, or HIV
• Living in endemic areas for specific fungi (Histoplasma, Coccidioides)
• Smoking or excessive alcohol use

Diagnosis

Diagnosing a JAK inhibitor–related infection involves a systematic approach: distinguishing infection from a disease flare, identifying the pathogen, and assessing severity.

Clinical Evaluation

1. History – onset, progression, exposure risks, recent travel, vaccination status, and medication timeline.
2. Physical examination – focus on rash, lung auscultation, abdominal tenderness, lymphadenopathy, and neurological status.

Laboratory Tests

• Complete blood count (CBC) with differential – look for leukocytosis, neutropenia, or lymphopenia.
• Inflammatory markers (CRP, ESR) – non‑specific but helpful to gauge severity.
• Comprehensive metabolic panel – assess liver/renal function.
• Serologies for latent infections before starting therapy (TB interferon‑γ release assay, hepatitis B surface antigen, hepatitis C antibody).
• Targeted cultures: blood, urine, sputum, wound swab, or cerebrospinal fluid as indicated.
• Viral PCR panels (HSV, VZV, CMV) when viral etiology is suspected.
• Fungal markers: serum (1‑3‑β‑D‑glucan, galactomannan) and bronchoalveolar lavage if pulmonary involvement.

Imaging Studies

• Chest X‑ray – first‑line for cough/fever.
• High‑resolution CT chest – more sensitive for interstitial pneumonitis, PCP, or fungal nodules.
• Abdominal ultrasound or CT – for intra‑abdominal infections.
• MRI brain – if neurologic signs suggest meningitis or encephalitis.

Diagnostic Scoring

Several rheumatology societies (e.g., ACR, EULAR) recommend using infection‑risk scoring tools that incorporate age, comorbidities, corticosteroid dose, and JAK inhibitor type to guide monitoring intensity.<sup>3</sup>

Treatment Options

Treatment is individualized based on the pathogen, infection severity, and the necessity to modify the JAK inhibitor regimen.

General Principles

• Prompt antimicrobial therapy according to culture/sensitivity or empiric guidelines.
• Temporary discontinuation or dose reduction of the JAK inhibitor – usually advised for moderate‑to‑severe infections.
• Supportive care: hydration, antipyretics, oxygen supplementation if needed.

Specific Therapies

Bacterial Infections

• Community‑acquired pneumonia – macrolide (azithromycin) or doxycycline; consider respiratory fluoroquinolone if risk factors present.
• Urinary tract infection – nitrofurantoin or trimethoprim‑sulfamethoxazole (TMP‑SMX), adjusting for renal function.
• Skin/soft‑tissue infection – cephalexin or clindamycin; MRSA coverage with doxycycline or TMP‑SMX if indicated.
• Severe infections/hospitalization – broad‑spectrum IV antibiotics (e.g., ceftriaxone + vancomycin) pending cultures.

Viral Infections

• Herpes Zoster – oral valacyclovir 1 g three times daily for 7 days (or acyclovir 800 mg five times daily). Consider IV acyclovir for disseminated disease.
• HSV – valacyclovir 1 g BID for 7‑10 days.
• CMV reactivation – valganciclovir 900 mg BID; monitor blood counts.

Fungal Infections

• Pneumocystis jirovecii pneumonia – high‑dose TMP‑SMX (15–20 mg/kg/day) for 21 days plus adjunctive steroids if PaO₂ < 70 mmHg.
• Candidiasis – fluconazole 200 mg daily for mucosal disease; IV echinocandin for invasive disease.
• Endemic mycoses (Histoplasma, Coccidioides) – itraconazole or fluconazole for 6–12 months, guided by specialist.

Management of Latent Infections

• Latent TB – isoniazid + rifapentine weekly for 12 weeks (or 9‑month isoniazid alone) before initiating a JAK inhibitor.
• HBV carrier – prophylactic entecavir or tenofovir started before JAK inhibitor and continued for at least 12 months after stopping.

Lifestyle and Adjunct Measures

• Vaccinations – non‑live vaccines (influenza, COVID‑19, pneumococcal) are strongly recommended before therapy; live vaccines are contraindicated while on JAK inhibitors.
• Smoking cessation and alcohol moderation to improve immune competence.
• Optimizing glycemic control and blood pressure.

Living with Janus Kinase (JAK) Inhibitor–Related Infections

Patients can lead active lives while on JAK inhibitors, but vigilance is key.

Daily Management Tips

• Medication log: Keep a written or digital record of dosing, missed doses, and any new symptoms.
• Regular labs: Schedule CBC, liver, and renal panels every 3 months (or as your provider advises).
• Self‑exam: Perform a brief skin check each morning; note any new rashes, lesions, or nodules.
• Symptom diary: Record fevers, cough, urinary changes, or GI upset promptly.
• Hydration and nutrition: Adequate protein and micronutrients (zinc, vitamin D) support immunity.
• Physical activity: Moderate exercise improves circulation and immune function, but avoid crowded gyms if you feel unwell.
• Travel precautions: Research endemic infections; carry a copy of your medication list and discuss prophylaxis with your rheumatologist.

Co‑ordination of Care

Maintain open communication with both your primary care physician and the specialist who prescribed the JAK inhibitor. If an infection is suspected, contact them early; many practices have a dedicated hotline for immunosuppressed patients.

Prevention

Prevention combines pre‑treatment screening, vaccination, lifestyle modification, and vigilant monitoring.

• Baseline screening: TB IGRA, hepatitis B surface antigen, hepatitis C antibody, HIV test, and CBC before the first dose.
• Vaccination schedule:
  • Influenza (annual, inactivated)
  • COVID‑19 (primary series + booster as indicated)
  • Pneumococcal (PCV20 or PCV13 followed by PPSV23)
  • Shingles (recombinant zoster vaccine, Shingrix) – safe for immunocompromised patients.
• Prophylactic antimicrobial therapy: In high‑risk individuals (e.g., those on concomitant steroids ≥ 20 mg prednisone), low‑dose TMP‑SMX 1 tablet three times weekly can reduce PCP risk.
• Hand hygiene & respiratory etiquette: Wash hands for at least 20 seconds; use masks in crowded indoor settings during respiratory virus season.
• Environmental precautions: Avoid construction sites or soil exposure in endemic fungal zones without protective masks.
• Regular follow‑up: Every 3‑6 months, review infection risk, adjust doses, and reassess the need for continued JAK inhibition.

Complications

If infections are not recognized or treated promptly, they can lead to serious, sometimes life‑threatening complications:

• Sepsis and septic shock – systemic inflammatory response, multi‑organ failure.
• Pneumonia progression – respiratory failure, need for mechanical ventilation.
• Disseminated herpes zoster – involvement of multiple dermatomes, visceral organ disease.
• Opportunistic infections – PCP, cryptococcal meningitis, disseminated histoplasmosis – high mortality if delayed.
• Hepatic decompensation – from viral hepatitis reactivation.
• Joint/implant infection – may necessitate surgical intervention.
• Long‑term organ damage – e.g., chronic kidney injury from severe pyelonephritis.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Janus kinase (JAK) inhibitors: What you need to know.” Updated 2023. mayoclinic.org
2. US Food & Drug Administration. “Safety Information for Tofacitinib (Xeljanz).” 2022. fda.gov
3. American College of Rheumatology. “2022 ACR Guideline for the Treatment of Rheumatoid Arthritis.” Arthritis Care Res (Hoboken). 2022;74(2):157‑175.
4. Cleveland Clinic. “Infection Risk with Biologics and JAK Inhibitors.” 2024. clevelandclinic.org
5. World Health Organization. “WHO Guidelines for the Management of Tuberculosis.” 2023. who.int

```